Elizabeth Cairns

Elizabeth Cairns

Senior Writer

London, UK

A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.

Latest from Elizabeth Cairns

Sanofi-Backed Resalis Brings MicroRNA To Obesity

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Idorsia And Medigene Cut Jobs To Keep Going

Both companies are seeking to license their products as they try to stretch their dwindling cash.

Alector Follows Cassava With An Alzheimer’s Miss

AL002 failed across the board in a mid-stage study, and Alector has trimmed its workforce as it refocuses on its other two assets.

AstraZeneca’s Truqap Hits In Prostate Cancer

Analysts are hoping for a sizeable benefit on PFS when the full data emerge.

Two Hepatitis D Candidates Take A Step Towards The Market

Recent data put Vir and Bluejay ahead of the pack, but it is hard to know exactly how well their products work.

GSK’s Linerixibat GLISTENs In PBC Itching

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.